{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:52:41Z","timestamp":1793836361496,"version":"4.6.1"},"reference-count":112,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.pharmthera.2021.107924","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T19:12:04Z","timestamp":1624561924000},"page":"107924","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Pharmacogenetics in diffuse large B-cell lymphoma treated with R-CHOP: Still an unmet challenge"],"prefix":"10.1016","volume":"229","author":[{"given":"Daniele","family":"Lavacchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Landini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Perrone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giandomenico","family":"Roviello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Mini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Nobili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2021.107924_bb0005","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0010","first-page":"1763","article-title":"Resistance to cytotoxic drugs in DNA mismatch repair-deficient cells","volume":"3","author":"Aebi","year":"1997","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0015","doi-asserted-by":"crossref","first-page":"4657","DOI":"10.1182\/blood-2011-04-346411","article-title":"The impact of Fc-\u03b3 receptor polymorphisms in elderly patients with diffuse large B-cell lymphoma treated with CHOP with or without rituximab","volume":"118","author":"Ahlgrimm","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0020","first-page":"709","article-title":"Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis","volume":"7","author":"Alas","year":"2001","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0025","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0030","doi-asserted-by":"crossref","first-page":"11592","DOI":"10.1073\/pnas.191211198","article-title":"Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia","volume":"98","author":"Allan","year":"2001","journal-title":"Proceedings of the National Academy of Sciences U. S. A."},{"key":"10.1016\/j.pharmthera.2021.107924_bb0035","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.18.00766","article-title":"Nivolumab for relapsed\/refractory diffuse large B-cell lymphoma in patients ineligible for or having failed autologous transplantation: A single-arm, phase II study","volume":"37","author":"Ansell","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0040","doi-asserted-by":"crossref","first-page":"3291","DOI":"10.1200\/JCO.19.01389","article-title":"Pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma","volume":"37","author":"Armand","year":"2019","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0045","first-page":"1459","article-title":"Clinical implications of glutathione S-transferase genotyping in patients with diffuse large B-cell lymphoma","volume":"21","author":"Atanaskovic","year":"2016","journal-title":"Journal of the Balkan Union of Oncology (J BUON)"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0050","doi-asserted-by":"crossref","first-page":"5099","DOI":"10.1158\/1078-0432.CCR-12-1590","article-title":"A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101","volume":"18","author":"Baldwin","year":"2012","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0055","doi-asserted-by":"crossref","first-page":"e199","DOI":"10.3324\/haematol.2016.159087","article-title":"Genetic polymorphism at BCL2 as a predictor for rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone efficacy in patients with diffuse large B-cell lymphoma","volume":"102","author":"Bashash","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0060","doi-asserted-by":"crossref","first-page":"4894","DOI":"10.1182\/blood-2004-12-4814","article-title":"The interleukin-10 gene promoter polymorphism (\u22121082) does not correlate with clinical outcome in diffuse large B-cell lymphoma","volume":"105","author":"Berglund","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0065","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/1471-2407-8-116","article-title":"MDM2 gene SNP309 T\/G and p53 gene SNP72 G\/C do not influence diffuse large B-cell non-Hodgkin lymphoma onset or survival in central European Caucasians","volume":"8","author":"Bittenbring","year":"2008","journal-title":"BMC Cancer"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0070","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1038\/sj.leu.2403536","article-title":"FcgammaRIIB expression in diffuse large B-cell lymphomas does not alter the response to CHOP+rituximab (R-CHOP)","volume":"18","author":"Camilleri-Bro\u00ebt","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0075","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1182\/blood.V99.3.754","article-title":"Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene","volume":"99","author":"Cartron","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0080","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s00280-009-1066-x","article-title":"Lymphotoxin alfa and receptor-interacting protein kinase 1 gene polymorphisms may correlate with prognosis in patients with diffuse large B cell lymphoma treated with R-CHOP","volume":"65","author":"Chae","year":"2010","journal-title":"Cancer Chemotherapy and Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0085","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/ejhg.2013.161","article-title":"A systematic review of cancer GWAS and candidate gene meta-analyses reveals limited overlap but similar effect sizes","volume":"22","author":"Chang","year":"2014","journal-title":"European Journal of Human Genetics"},{"issue":"9","key":"10.1016\/j.pharmthera.2021.107924_bb0090","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1002\/ajh.23273","article-title":"Germline variation in complement genes and event-free survival in follicular and diffuse large B-cell lymphoma","volume":"87","author":"Charbonneau","year":"2012","journal-title":"American Journal of Hematolology"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0095","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.cancergencyto.2009.12.004","article-title":"Glutathione-S-transferase genotypes influence the risk of chemotherapy-related toxicities and prognosis in Korean patients with diffuse large B-cell lymphoma","volume":"198","author":"Cho","year":"2010","journal-title":"Cancer Genetics and Cytogenetics"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0100","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0105","doi-asserted-by":"crossref","first-page":"4127","DOI":"10.1158\/1078-0432.CCR-16-2818","article-title":"A phase 2\/3 multicenter, randomized, open-label study to compare the efficacy and safety of lenalidomide versus investigator\u2019s choice in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"23","author":"Czuczman","year":"2017","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0110","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1158\/0008-5472.CAN-03-2862","article-title":"Rituximab-dependent cytotoxicity by natural killer cells: Influence of FCGR3A polymorphism on the concentration-effect relationship","volume":"64","author":"Dall\u2019Ozzo","year":"2004","journal-title":"Cancer Research"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0115","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30935-5","article-title":"Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): An open-label, randomised, phase 3 trial","volume":"20","author":"Davies","year":"2019","journal-title":"Lancet Oncology"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0120","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.3389\/fonc.2019.01417","article-title":"Precision medicine in lymphoma by innovative instrumental platforms","volume":"9","author":"Di Paolo","year":"2019","journal-title":"Frontiers in Oncology"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0125","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/1475-2867-13-58","article-title":"Single nucleotide polymorphisms of CD20 gene and their relationship with clinical efficacy of R-CHOP in patients with diffuse large B cell lymphoma","volume":"13","author":"Ding","year":"2013","journal-title":"Cancer Cell International"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0130","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.1182\/blood-2009-01-199679","article-title":"Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma","volume":"113","author":"Dunleavy","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0135","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.ctrv.2008.07.003","article-title":"An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment","volume":"35","author":"Ekhart","year":"2009","journal-title":"Cancer Treatment Reviews"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0140","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.blre.2017.02.005","article-title":"How gene polymorphisms can influence clinical response and toxicity following R-CHOP therapy in patients with diffuse large B cell lymphoma","volume":"31","author":"Falduto","year":"2017","journal-title":"Blood Reviews"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0145","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/hon.2305","article-title":"FCGR3A\/2A polymorphisms and diffuse large B-cell lymphoma outcome treated with immunochemotherapy: A meta-analysis on 1134 patients from two prospective cohorts","volume":"35","author":"Ghesqui\u00e8res","year":"2017","journal-title":"Hematology & Oncology"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0150","doi-asserted-by":"crossref","first-page":"3930","DOI":"10.1200\/JCO.2014.60.2573","article-title":"Genome-wide association study of event-free survival in diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"33","author":"Ghesquieres","year":"2015","journal-title":"Journal Clinical of Oncology"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0155","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2141.2009.07942.x","article-title":"Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP)","volume":"148","author":"Gratzinger","year":"2010","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0160","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/ajh.23709","article-title":"Genetic polymorphisms in oxidative stress-related genes are associated with outcomes following treatment for aggressive B-cell non-Hodgkin lymphoma","volume":"89","author":"Gustafson","year":"2014","journal-title":"American Journal of Hematology"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0165","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1097\/FPC.0000000000000262","article-title":"Rituximab response in follicular lymphoma is associated with the rs20575 polymorphism in TRAILR1 extrinsic apoptosis trigger","volume":"27","author":"Guti\u00e9rrez-C\u00edvicos","year":"2017","journal-title":"Pharmacogenetics and Genomics"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0170","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00008571-200401000-00005","article-title":"Promoter polymorphisms in glutathione-S-transferase genes affect transcription","volume":"14","author":"Guy","year":"2004","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0175","first-page":"201","article-title":"Genetic polymorphisms of ATP-binding cassette (ABC) proteins, overall survival and drug toxicity in patients with Acute Myeloid Leukemia","volume":"1","author":"Hampras","year":"2010","journal-title":"International Journal of Molecular Epidemiology and Genetics"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0180","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/ajh.21580","article-title":"Genetic polymorphisms in the metabolic pathway and non-Hodgkin lymphoma survival","volume":"85","author":"Han","year":"2010","journal-title":"American Journal of Hematology"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0185","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/ejh.12388","article-title":"The MDM2 polymorphism SNP309 is associated with clinical characteristics and outcome in diffuse large B-cell lymphoma","volume":"93","author":"Hedstr\u00f6m","year":"2014","journal-title":"European Journal of Haematology"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0190","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1111\/j.1365-2125.2010.03789.x","article-title":"The combined impact of CYP2C19 and CYP2B6 pharmacogenetics on cyclophosphamide bioactivation","volume":"70","author":"Helsby","year":"2010","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0195","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3109\/10428194.2012.736980","article-title":"MDR1 polymorphisms associated with risk and survival in diffuse large B-cell lymphoma","volume":"54","author":"Hu","year":"2013","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0200","first-page":"42","article-title":"Pharmacogenetics and pharmacogenomics of anticancer agents","volume":"59","author":"Huang","year":"2009","journal-title":"CA: a Cancer Journal for Clinicians"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0205","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1007\/s00277-020-04008-3","article-title":"Plasma cell-free DNA is a prognostic biomarker for survival in patients with aggressive non-Hodgkin lymphomas","volume":"99","author":"Hur","year":"2020","journal-title":"Annals of Hematology"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0210","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A predictive model for aggressive non-Hodgkin\u2019s lymphoma","volume":"329","author":"International Non-Hodgkin\u2019s Lymphoma Prognostic Factors Project","year":"1993","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0215","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/1756-8722-5-51","article-title":"Homozygous A polymorphism of the complement C1qA276 correlates with prolonged overall survival in patients with diffuse large B cell lymphoma treated with R-CHOP","volume":"5","author":"Jin","year":"2012","journal-title":"Journal of Hematology & Oncology"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0220","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1182\/blood-2013-07-516666","article-title":"CYP2B6*6 is an independent determinant of inferior response to fludarabine plus cyclophosphamide in chronic lymphocytic leukemia","volume":"122","author":"Johnson","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0225","doi-asserted-by":"crossref","first-page":"e204","DOI":"10.3324\/haematol.2014.120113","article-title":"Single nucleotide polymorphisms in ABCB1 and CBR1 can predict toxicity to R-CHOP type regimens in patients with diffuse non-Hodgkin lymphoma","volume":"100","author":"Jordheim","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0230","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/j.1445-5994.2011.02587.x","article-title":"Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma","volume":"42","author":"Keane","year":"2012","journal-title":"Internal Medicine Journal"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0235","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1182\/blood-2006-01-009480","article-title":"FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma","volume":"108","author":"Kim","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0240","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/j.1349-7006.2008.00985.x","article-title":"ABCG2 Q141K polymorphism is associated with chemotherapy-induced diarrhea in patients with diffuse large B-cell lymphoma who received frontline rituximab plus cyclophosphamide\/doxorubicin\/vincristine\/prednisone chemotherapy","volume":"99","author":"Kim","year":"2008","journal-title":"Cancer Sciences"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0245","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1349-7006.2011.02168.x","article-title":"VEGFA and VEGFR2 genetic polymorphisms and survival in patients with diffuse large B cell lymphoma","volume":"103","author":"Kim","year":"2012","journal-title":"Cancer Science"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0250","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jamaneurol.2015.1276","article-title":"Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: Influence of FCGR3A polymorphisms on the therapeutic response to rituximab","volume":"72","author":"Kim","year":"2015","journal-title":"JAMA Neurology"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0255","doi-asserted-by":"crossref","first-page":"9798","DOI":"10.18632\/oncotarget.2394","article-title":"Hypermethylation of DAPK1 is an independent prognostic factor predicting survival in diffuse large B-cell lymphoma","volume":"5","author":"Kristensen","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0260","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1182\/blood-2003-06-1850","article-title":"Interleukin-10 gene promoter polymorphisms influence the clinical outcome of diffuse large B-cell lymphoma","volume":"103","author":"Lech-Maranda","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0265","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0270","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s00277-016-2857-x","article-title":"Polymorphisms in cytokine genes as prognostic markers in diffuse large B cell lymphoma patients treated with (R)-CHOP","volume":"96","author":"Liu","year":"2017","journal-title":"Annals of Hematology"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0275","doi-asserted-by":"crossref","first-page":"58292","DOI":"10.18632\/oncotarget.16869","article-title":"ABCG2 and NCF4 polymorphisms are associated with clinical outcomes in diffuse large B-cell lymphoma patients treated with R-CHOP","volume":"8","author":"Liu","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0280","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1089\/dna.2013.2333","article-title":"FCGR3A 158V\/F polymorphism and response to frontline R-CHOP therapy in diffuse large B-cell lymphoma","volume":"33","author":"Liu","year":"2014","journal-title":"DNA Cell Biology"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0285","doi-asserted-by":"crossref","first-page":"3879","DOI":"10.1073\/pnas.1121343109","article-title":"Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing","volume":"109","author":"Lohr","year":"2012","journal-title":"Proceedings of the National Academy of Sciences U. S. A."},{"key":"10.1016\/j.pharmthera.2021.107924_bb0290","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3109\/10428194.2014.916798","article-title":"Treatment of aggressive B-cell lymphoma in elderly patients: Influence of single nucleotide polymorphisms affecting pharmacodynamics of chemotherapeutics","volume":"56","author":"Melchardt","year":"2015","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0295","first-page":"17","article-title":"Pharmacogenetics: Implementing personalized medicine","volume":"6","author":"Mini","year":"2009","journal-title":"Clinical Cases in Mineral and Bone Metabolism"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0300","first-page":"225","article-title":"\u201cPharmacogenetics of cancer\u201d - Cancer drug resistance special issue","volume":"3","author":"Mini","year":"2020","journal-title":"Cancer Drug Resistance"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0305","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0310","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1016\/j.bbmt.2011.10.010","article-title":"High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: An analysis based on data from the European Blood and Marrow Transplantation Registry","volume":"18","author":"Mounier","year":"2012","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0315","author":"National Comprehensive Cancer Network"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0320","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0325","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.semcancer.2019.08.006","article-title":"Role of ATP-binding cassette transporters in cancer initiation and progression","volume":"60","author":"Nobili","year":"2020","journal-title":"Seminars in Cancer Biology"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0330","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.3109\/10428194.2013.866665","article-title":"Identification of pharmacogenomic markers of clinical efficacy in a dose-dense therapy regimen (R-CHOP14) in diffuse large B-cell lymphoma","volume":"55","author":"Nobili","year":"2014","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0335","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.2014.55.5714","article-title":"Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-cell lymphoma: A phase II study","volume":"33","author":"Nowakowski","year":"2015","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0340","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cancergencyto.2008.02.001","article-title":"FcgammaRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients","volume":"183","author":"Paiva","year":"2008","journal-title":"Cancer Genetics and Cytogenetics"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0345","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000485","article-title":"Effect of Fc\u03b3-receptor 3a (FCGR3A) gene polymorphisms on rituximab therapy in Hungarian patients with rheumatoid arthritis","volume":"3","author":"P\u00e1l","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0350","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1158\/1078-0432.CCR-08-1588","article-title":"Interaction between BCL2 and interleukin-10 gene polymorphisms alter outcomes of diffuse large B-cell lymphoma following rituximab plus CHOP chemotherapy","volume":"15","author":"Park","year":"2009","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0355","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1182\/blood-2017-11-764332","article-title":"Genetics of diffuse large B-cell lymphoma","volume":"131","author":"Pasqualucci","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0360","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/ng.892","article-title":"Analysis of the coding genome of diffuse large B-cell lymphoma","volume":"43","author":"Pasqualucci","year":"2011","journal-title":"Nature Genetics"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0365","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1470-2045(08)70002-0","article-title":"Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: A randomised controlled trial (RICOVER-60)","volume":"9","author":"Pfreundschuh","year":"2008","journal-title":"Lancet Oncology"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0370","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0375","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.2217\/pgs.09.134","article-title":"Drug focus: Pharmacogenetic studies related to cyclophosphamide-based therapy","volume":"10","author":"Pinto","year":"2009","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0380","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2217\/pgs.14.179","article-title":"Association of NADPH oxidase polymorphisms with anthracycline-induced cardiotoxicity in the RICOVER-60 trial of patients with aggressive CD20(+) B-cell lymphoma","volume":"16","author":"Reichwagen","year":"2015","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0385","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1038\/sj.onc.1209377","article-title":"Cytochrome P450 pharmacogenetics and cancer","volume":"25","author":"Rodriguez-Antona","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0390","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1182\/blood-2010-07-296244","article-title":"The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma","volume":"117","author":"Rossi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0395","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1038\/leu.2008.398","article-title":"Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21","volume":"23","author":"Rossi","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0400","doi-asserted-by":"crossref","first-page":"648","DOI":"10.3324\/haematol.2018.206177","article-title":"Liquid biopsy in lymphoma","volume":"104","author":"Rossi","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0405","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1200\/JCO.2010.31.1142","article-title":"Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma","volume":"29","author":"Ruan","year":"2011","journal-title":"Journal of Clinical Oncolology"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0410","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv279","article-title":"Analysis of heritability and shared heritability based on genome-wide association studies for thirteen cancer types","volume":"107","author":"Sampson","year":"2015","journal-title":"Journal of the National Cancer Institute"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0415","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0420","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1078-0432.CCR-16-0908","article-title":"Genome-wide association study for anthracycline-induced congestive heart failure","volume":"23","author":"Schneider","year":"2017","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0425","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0430","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","article-title":"The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP","volume":"109","author":"Sehn","year":"2007","journal-title":"Blood"},{"issue":"15_suppl","key":"10.1016\/j.pharmthera.2021.107924_bb0435","doi-asserted-by":"crossref","first-page":"7507","DOI":"10.1200\/JCO.2018.36.15_suppl.7507","article-title":"Randomized phase 2 trial of polatuzumab vedotin (pola) with bendamustine and rituximab (BR) in relapsed\/refractory (r\/r) FL and DLBCL","volume":"36","author":"Shen","year":"2018","journal-title":"Journal of Clininical Oncology"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0440","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1080\/09629350123387","article-title":"Tumor necrosis factor-alpha\/interleukin-10 balance in normal and cystic fibrosis children","volume":"10","author":"Shmarina","year":"2001","journal-title":"Mediators of Inflammation"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0445","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/jcph.878","article-title":"Cytochrome P450 genetic variations can predict mRNA expression, cyclophosphamide 4-hydroxylation, and treatment outcomes in Chinese patients with non-Hodgkin\u2019s lymphoma","volume":"57","author":"Shu","year":"2017","journal-title":"Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0450","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1097\/FPC.0b013e328348e48f","article-title":"Genome-wide association study of epirubicin-induced leukopenia in Japanese patients","volume":"21","author":"Srinivasan","year":"2011","journal-title":"Pharmacogenetics and Genomics"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0455","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0460","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/s41576-019-0127-1","article-title":"Benefits and limitations of genome-wide association studies","volume":"20","author":"Tam","year":"2019","journal-title":"Nature Reviews Genetics"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0465","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s10147-013-0531-z","article-title":"Association of interleukin-10, tumor necrosis factor-\u03b1 and transforming growth factor-\u03b2 gene polymorphisms with the outcome of diffuse large B-cell lymphomas","volume":"19","author":"Tarabar","year":"2014","journal-title":"International Journal of Clinical Oncology"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0470","first-page":"443","article-title":"2016 US lymphoid malignancy statistics by World Health Organization subtypes","volume":"66","author":"Teras","year":"2016","journal-title":"CA: a Cancer Journal for Clinicians"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0475","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1158\/1078-0432.CCR-08-1403","article-title":"Identification of CD20 C-terminal deletion mutations associated with loss of CD20 expression in non-Hodgkin's lymphoma","volume":"15","author":"Terui","year":"2009","journal-title":"Clinical Cancer Research"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0480","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejca.2015.12.007","article-title":"Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma","volume":"55","author":"Veal","year":"2016","journal-title":"European Journal of Cancer"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0485","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/bjh.13237","article-title":"Prognostic impact of the TP53 rs1625895 polymorphism in DLBCL patients","volume":"169","author":"Voropaeva","year":"2015","journal-title":"British Journal of Haematology"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0490","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1038\/leu.2013.95","article-title":"Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: A phase II clinical trial","volume":"27","author":"Wang","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0495","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1080\/10428190902829441","article-title":"Genetic polymorphism of the inhibitory IgG Fc receptor FcgammaRIIb is not associated with clinical outcome in patients with follicular lymphoma treated with rituximab","volume":"50","author":"Weng","year":"2009","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0500","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nature Medicine"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0505","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1161\/CIRCULATIONAHA.105.576850","article-title":"NAD(P)H oxidase and multidrug resistance protein genetic polymorphisms are associated with doxorubicin-induced cardiotoxicity","volume":"112","author":"Wojnowski","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0510","doi-asserted-by":"crossref","first-page":"W600","DOI":"10.1093\/nar\/gkp290","article-title":"SNPinfo: Integrating GWAS and candidate gene information into functional SNP selection for genetic association studies","volume":"37","author":"Xu","year":"2009","journal-title":"Nucleic Acids Research"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0515","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1182\/blood-2012-12-473702","article-title":"MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: A report from the International DLBCL Rituximab-CHOP Consortium Program","volume":"122","author":"Xu-Monette","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0520","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00277-014-2170-5","article-title":"UGT1A1 *6 polymorphism predicts outcome in elderly patients with relapsed or refractory diffuse large B-cell lymphoma treated with carboplatin, dexamethasone, etoposide and irinotecan","volume":"94","author":"Yamasaki","year":"2015","journal-title":"Annals of Hematology"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0525","doi-asserted-by":"crossref","first-page":"565","DOI":"10.2144\/000112043","article-title":"Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development","volume":"39","author":"Yan","year":"2005","journal-title":"Biotechniques"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0530","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1080\/10428194.2017.1300893","article-title":"Adverse prognostic impact of vascular endothelial growth factor gene polymorphisms in patients with diffuse large B-cell lymphoma","volume":"58","author":"Yoon","year":"2017","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0535","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.3109\/10428194.2013.774392","article-title":"Influence of polymorphisms in genes encoding immunoregulatory proteins and metabolizing enzymes on susceptibility and outcome in patients with diffuse large B-cell lymphoma treated with rituximab","volume":"54","author":"Yri","year":"2013","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0540","doi-asserted-by":"crossref","first-page":"676","DOI":"10.3109\/10428194.2014.927455","article-title":"The significance of single nucleotide polymorphism rs2070770 in CD20 gene in Chinese patients with diffuse large B-cell lymphoma","volume":"56","author":"Zhang","year":"2015","journal-title":"Leukemia & Lymphoma"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0545","first-page":"198","article-title":"Fcgamma receptor IIIA polymorphisms and efficacy of rituximab therapy on Chinese diffuse large B-cell lymphoma","volume":"123","author":"Zhang","year":"2010","journal-title":"Chinese Medical Journal (England)"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0550","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","article-title":"An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era","volume":"23","author":"Zhou","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0555","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1080\/15384047.2018.1537575","article-title":"The VEGFR-2 protein and the VEGFR-2 rs1870377 A>T genetic polymorphism are prognostic factors for gastric cancer","volume":"20","author":"Zhu","year":"2019","journal-title":"Cancer Biology & Therapy"},{"key":"10.1016\/j.pharmthera.2021.107924_bb0560","first-page":"1454","article-title":"Fc\u03b3RIIa-H131R variant is associated with inferior response in diffuse large B cell lymphoma: A meta-analysis of genetic risk","volume":"21","author":"Ziakas","year":"2016","journal-title":"Journal of the Balkan Union of Oncology"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725821001261?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725821001261?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:18:16Z","timestamp":1759011496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725821001261"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":112,"alternative-id":["S0163725821001261"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107924","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacogenetics in diffuse large B-cell lymphoma treated with R-CHOP: Still an unmet challenge","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107924","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107924"}}